Lenvakast 10mg Capsule (Lenvatinib)

Lenvakast 10mg Capsule is a targeted therapy-based anticancer medicine. It is used in the treatment of various types of cancer, including differentiated thyroid cancer, liver cancer, kidney cancer, and endometrial cancer. It contains Lenvatinib as an active ingredient that belongs to the tyrosine kinase inhibitor (TKI) class of drugs. It works by blocking the action of a specific protein to stop the growth and multiplication of cancer cells and the formation of new blood vessels. Lenvatinib 10mg capsule is used in differentiated thyroid cancer that is no longer responsive to radioactive iodine therapy and advanced renal cell carcinoma in combination therapy.

The capsule must be taken orally and swallowed whole with water and should not be crushed, chewed, or opened. The prescribed dose and duration of the Lenvatinib 10mg capsule depend on the patient's condition and response to treatment. It can also be taken with or without food. Patients are advised not to change the dosage and timings prescribed by the doctors because it can cause severe side effects.

Common side effects include tiredness, decreased appetite, nausea, vomiting, diarrhea, weight loss, mouth sores, headache, high blood pressure, and changes in thyroid function. A few patients can undergo severe side effects, including severe chest pain, difficulty breathing, severe headache or confusion, significant bleeding and severe abdominal pain. Most of the Lenvatinib 10mg capsule side effects can leave when the body adapts to the medicine. However, if any side effects persist, inform your doctor immediately.

Women who can become pregnant should use effective contraception during the treatment. Patients must list all medicines, supplements, and herbal products that they are taking. The Lenvatinib 10mg capsule must be used under medical oversight or medical supervision only. Attend regular tests and follow-ups to monitor the medicine response and reduce side effects. Before making any adjustments, changing the dose, or stopping the treatment, consult with your doctor to maximize the benefit.

Thyroid Cancer

Every medicine has some side effects that typically manage on their own as your body gets used to the medicine, but some people may experience severe side effects rarely. In that case, the patient should contact the doctor immediately.
Some common side effects of Lenvakast 10mg Capsule (Lenvatinib 10mg) include:
● Severe headache
● Fever
● Confusion
● Difficulty speaking
● Vision changes
● Dizziness
● Chest pain or pressure
● Pain in arms, jaw, neck, and back
● Breathing problems
● Severe stomach pain
● Blood clot formation
● Blood in stools or coughing blood
● Liver problems
● Pain or soreness in the mouth, teeth, or jaw
Contact your healthcare provider if you face any unusual or persistent side effects.

Take Lenvakast 10mg Capsule (Lenvatinib 10mg) in exact dose as prescribed by the doctor. The typical dose of this capsule varies with age, type & stage of the cancer, and overall health factor of the patient.

It can be taken with or without food but at a fixed time each day to get better results. It should be swallowed as a whole with water without crushing, chewing, or opening the capsule. Don't miss a dose or overdose the medicine.

Instructions if you miss a dose

● Makker, V., Taylor, M. H., Aghajanian, C., Oaknin, A., Mier, J., Cohn, A. L., ... & Casado Herraez, A. (2020). Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. Journal of clinical oncology, 38(26), 2981-2992.
● Kudo, M., Finn, R. S., Qin, S., Han, K. H., Ikeda, K., Piscaglia, F., ... & Cheng, A. L. (2018). Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. The Lancet, 391(10126), 1163-1173.
● Hatanaka, T., Naganuma, A., & Kakizaki, S. (2021). Lenvatinib for hepatocellular carcinoma: a literature review. Pharmaceuticals, 14(1), 36.
● Scott, L. J. (2015). Lenvatinib: first global approval. Drugs, 75(5), 553-560.
● Hao, Z., & Wang, P. (2020). Lenvatinib in management of solid tumors. The oncologist, 25(2), e302-e310.
● Suyama, K., & Iwase, H. (2018). Lenvatinib: a promising molecular targeted agent for multiple cancers. Cancer control, 25(1), 1073274818789361.